What is the appropriate management and treatment for Staphylococcus intermedius isolated from a urine culture?

Management of Staphylococcus intermedius Isolated from Urine Culture

Staphylococcus intermedius bacteriuria in humans is exceedingly rare and likely represents either specimen contamination, laboratory misidentification (most commonly confused with S. aureus), or—if the patient has animal contact—a true zoonotic infection requiring the same investigative approach as S. aureus bacteriuria.

Critical First Step: Confirm Species Identification

• S. intermedius is a veterinary pathogen primarily isolated from canine skin and ear infections, not human urinary tract infections 1, 2, 3.
• Modern matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF) and molecular methods can accurately distinguish S. intermedius group organisms from S. aureus, whereas older biochemical methods frequently misidentify them 4.
• Request laboratory confirmation that the isolate is truly S. intermedius and not S. aureus or S. pseudintermedius, as misidentification directly impacts antimicrobial susceptibility testing interpretation and treatment selection 4.

Determine Clinical Significance

Assess for Contamination vs. True Infection

• S. aureus (and by extension S. intermedius) accounts for only 0.2–4% of positive urine cultures and often represents contamination rather than infection 5.
• True urinary tract infection is more likely if:
  • Pyuria is present on urinalysis (≥10 WBC/hpf) 5, 6
  • Patient has dysuria, frequency, urgency, suprapubic pain, or fever 6
  • Urinary catheter is in place 5
  • Recent urological instrumentation or structural abnormality exists 7, 5
  • Male sex, older age, diabetes, or long-term care residence 5

Rule Out Bacteremic Seeding

• Obtain blood cultures in patients with:
  • Fever, rigors, or systemic toxicity 5, 6
  • Recent or planned urological instrumentation 5
  • Indwelling urinary catheter 5
  • Immunocompromised status 8
  • Persistent or recurrent bacteriuria 5
• In one retrospective series, 6.5% of patients with S. aureus bacteriuria had concurrent bacteremia, with 4 of 6 cases associated with urological procedures 5.
• Do not routinely obtain blood cultures in well-appearing outpatients without risk factors, as the yield is low 5.

Evaluate for Metastatic Foci if Bacteremia is Present

• If blood cultures are positive, perform transthoracic echocardiography to assess for endocarditis 9, 10.
• Obtain imaging (CT or MRI) guided by symptoms: back pain (vertebral osteomyelitis), joint pain (septic arthritis), abdominal pain (visceral abscess) 9, 10.
• Repeat blood cultures at 2–4 days to document clearance; persistent bacteremia (≥48 hours) carries 39% 90-day mortality and mandates aggressive source control 9, 10.

Antimicrobial Therapy

Asymptomatic Bacteriuria

• Do not treat asymptomatic S. intermedius bacteriuria in well-appearing patients without planned urological procedures 5.
• Consider repeat urine culture in 1–2 weeks to document clearance, especially in patients with urinary catheters, structural abnormalities, or diabetes 5.

Symptomatic Urinary Tract Infection

• Empiric therapy pending susceptibilities:

  • Trimethoprim-sulfamethoxazole (TMP-SMX) is effective for most S. intermedius isolates (>90% susceptible in veterinary studies) and S. aureus urinary isolates (91% susceptible) 2, 6.
  • Alternative oral agents include cephalexin (>95% of S. intermedius susceptible to cephalosporins), doxycycline, or fluoroquinolones 2, 3, 6.
  • If MRSA risk is high (healthcare-associated infection, prior MRSA, local resistance >10%), use TMP-SMX, doxycycline, or linezolid pending susceptibilities 11.

• Definitive therapy based on susceptibilities:

  • For methicillin-susceptible isolates, use cefazolin, cephalexin, or an antistaphylococcal penicillin 10.
  • For methicillin-resistant isolates (24% of S. aureus urinary isolates in one series), use vancomycin, linezolid, or TMP-SMX if susceptible 6.
  • Vancomycin, teicoplanin, and linezolid retain 100% susceptibility against S. aureus urinary isolates 6.

• Duration:

  • Treat uncomplicated cystitis for 7 days 7.
  • Treat complicated urinary tract infection (catheter-associated, structural abnormality, male sex, pyelonephritis) for 10–14 days 7.
  • If bacteremia is present, treat for ≥14 days from the first negative blood culture, or longer if metastatic foci exist 10.

Source Control

• Remove urinary catheters whenever feasible, as catheterization is a major risk factor for recurrence 5.
• Drain abscesses or collections identified on imaging 10.
• Correct underlying urological abnormalities (obstruction, stones, neurogenic bladder) to prevent recurrence 7, 5.

Follow-Up and Recurrence Prevention

• Repeat urine culture 1–2 weeks after completing antibiotics in patients with catheters, structural abnormalities, diabetes, or inpatient status, as these factors are associated with 50% recurrence by 4–6 weeks 7, 5.
• If recurrence occurs despite correcting underlying abnormalities, consider suppressive antimicrobial therapy, though this is not well-studied for staphylococcal bacteriuria 7.
• Educate patients on hand hygiene and wound care if animal contact is the suspected source, as S. intermedius is a canine commensal 1, 2.

Key Pitfalls to Avoid

• Do not assume the isolate is S. aureus without confirmatory testing, as S. intermedius group organisms require specific susceptibility interpretation 4.
• Do not treat asymptomatic bacteriuria in well patients, as this promotes resistance without clinical benefit 5.
• Do not omit blood cultures in high-risk patients (fever, instrumentation, catheter), as occult bacteremia may be present 5.
• Do not use swabs for urine collection; obtain clean-catch midstream or catheterized specimens to minimize contamination 8.